Navigation Links
Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
Date:3/9/2009

CINCINNATI, March 9 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced Chief Operating Officer Christopher Bergen will participate in the Barclays Capital Global Healthcare Conference on March 10 as well as the Raymond James 30th Annual Institutional Investors Conference on March 11.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )

Barclays Capital Global Healthcare Conference

The Barclays Capital Global Healthcare Conference will be held March 10-11 at the Loews Miami Beach Hotel in Miami. The Kendle presentation by Mr. Bergen is scheduled for Tuesday, March 10 at 9 a.m. Eastern Time.

The presentation will be Webcast and may be accessed at www.kendle.com in the "Investors Events & Presentations" section or at http://cc.talkpoint.com/barc002/030909a_rb/?entity=107_X2FCIEE. Slides will be available by 7 a.m. on the day of the presentation at www.kendle.com in the "Investors Events & Presentations" section.

Raymond James 30th Annual Institutional Investors Conference

The Raymond James 30th Annual Institutional Investors Conference will be held March 9-11 at the JW Marriott in Orlando, Fla. The Kendle presentation by Mr. Bergen is scheduled for Wednesday, March 11 at 7:30 a.m. Eastern Time.

The presentation will be Webcast and may be accessed at www.kendle.com in the "Investors Events & Presentations" section or at http://wsw.com/webcast/rj43/kndl/. Slides will be available by 6 a.m. on the day of the presentation at www.kendle.com in the "Investors Events & Presentations" section.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Kendle was recognized by FORTUNE magazine as one of the 100 fastest- growing companies in the United States for 2008. The company also has been recognized as "Top CRO to Work With" in the CenterWatch 2007 survey of U.S. investigative sites and among the "Top CROs in Europe" in the 2008 survey of European sites.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call
2. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
3. Kendle to Present at the 2008 Credit Suisse Health Care Conference
4. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
5. Kendle Named a Best Place to Work in Greater Cincinnati
6. Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
7. Kendle Named to FORTUNE List of 100 Fastest-Growing Companies for 2008
8. Kendle to Present at the UBS Global Life Sciences Conference
9. Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast
10. Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress
11. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority ... announced that Charles W. Stellar has been named by the WEDI Board of Directors ... 2016. As an executive leader with more than 35 years of experience in healthcare, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company ... granted the company’s orphan drug designation request covering BHV-4157 for the treatment of ... the FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that ...
(Date:5/24/2016)... Israel , May 24, 2016   MedyMatch Technology ... physicians with artificial intelligence, real-time decision support tools in the ... present at the 2016 Israeli Advanced Technology Industries (IATI) BioMed ... Israel,s 15th National Life Sciences and ... at the David Intercontinental Hotel in Tel Aviv, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Media Cybernetics, ... new Media Cybernetics corporate branding reflects a results-driven revitalization for a company with ... The re-branding components include a crisp, refreshed logo and a new web presence. ...
Breaking Biology Technology:
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... (NSO), which operates the highest sample volume laboratory in ... Tute Genomics and UNIConnect, leaders in clinical sequencing informatics ... the launch of a project to establish the informatics ... NSO has been contracted by the ...
Breaking Biology News(10 mins):